Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA. 2 and BA. 5 subvariant predominance: A systematic literature …
M Drysdale, M Berktas, DC Gibbons, C Rolland… - Infection, 2024 - Springer
Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
W Guo, Y Zheng, S Feng - Frontiers in Cellular and Infection …, 2023 - frontiersin.org
The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due
to its high transmissibility, although it appears to be less pathogenic than previous strains …
to its high transmissibility, although it appears to be less pathogenic than previous strains …
[HTML][HTML] Efficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis
The impact of COVID-19 vaccination on clinical outcomes in solid organ transplant (SOT)
recipients remains unclear. This systematic review and network meta-analysis (NMA) sought …
recipients remains unclear. This systematic review and network meta-analysis (NMA) sought …
[HTML][HTML] Antiviral activities of sotrovimab against BQ. 1.1 and XBB. 1.5 in sera of treated patients
T Bruel, LL Vrignaud, F Porrot, I Staropoli, D Planas… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background Monoclonal antibodies (mAbs) targeting the spike of SARS-CoV-2 prevent
severe COVID-19. Omicron subvariants BQ. 1.1 and XBB. 1.5 evade neutralization of …
severe COVID-19. Omicron subvariants BQ. 1.1 and XBB. 1.5 evade neutralization of …
Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future …
Solid organ transplant recipients (SOTRs), including heart transplant (HT) recipients,
infected with Coronavirus disease 2019 (COVID-19) are at higher risk of hospitalization …
infected with Coronavirus disease 2019 (COVID-19) are at higher risk of hospitalization …
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium
M Drysdale, T Hautekiet, M Singh, J Hautekiet… - Acta Clinica …, 2024 - Taylor & Francis
Objective Sotrovimab, a dual-action, engineered human monoclonal antibody, has been
demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients …
demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients …
Clinical practice guideline–supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre
K Hammond, F Bourdeau, M Klein… - Journal of the …, 2024 - utppublishing.com
Background: Immunocompromised patients remain at risk of progression to severe COVID-
19 disease. Methods: We describe clinical COVID-19-related outcomes after administration …
19 disease. Methods: We describe clinical COVID-19-related outcomes after administration …